The Selective Neurokinin 3 Antagonist AZD2624 Does Not Improve Symptoms or Cognition in Schizophrenia

Tachykinin neurokinin 3 receptor antagonists: a patent review (2005 – 2010)

(2011) Pari Malherbe et al.   EXPERT OPINION ON THERAPEUTIC PATENTS

In vitroassessment of metabolic drug–drug interaction potential of AZD2624, neurokinin-3 receptor antagonist, through cytochrome P450enzyme identification, inhibition, and induction studies

(2010) Yan Li et al.   XENOBIOTICA

In vitro and in vivo comparison of two non-peptide tachykinin NK3 receptor antagonists: Improvements in efficacy achieved through enhanced brain penetration or altered pharmacological characteristics

(2009) Lee A. Dawson et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

A comparison of the CogState Schizophrenia Battery and the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Battery in assessing cognitive impairment in chronic schizophrenia

(2009) Robert H. Pietrzak et al.   JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY

Quantitative PET Analysis of the Dopamine D2 Receptor Agonist Radioligand 11C-(R)-2-CH3O-N-n-Propylnorapomorphine in the Human Brain

(2009) T. Otsuka et al.   JOURNAL OF NUCLEAR MEDICINE

Augmentation of antipsychotic-induced neurochemical changes by the NK3 receptor antagonist talnetant (SB-223412)

(2008) Raúl de la Flor et al.   NEUROPHARMACOLOGY